The Evolution Of Clinical Research In East Asia
PHARMACEUTICAL CLINICAL RESEARCH APPEARS TO BE SHIFTING FROM JAPAN TOWARDS CHINA AND SOUTH KOREA
Jun 09, 2015, 02:15 ET
NEW YORK, June 9, 2015 /PRNewswire/ -- Citeline®, an Informa business unit, and the pharmaceutical industry's leading research authority on clinical trials, reported today that clinical trials in East Asia have increased dramatically over a recent 10 year period, driven primarily by local studies conducted by a single sponsor.
The findings were presented today at the Pharma CI Conference & Exhibition Asia in Tokyo Japan, an event attended by top competitive intelligence professionals in the Japanese pharmaceutical industry. The full report, written by Doro Shin, a well published Citeline analyst, is now publically available.
For her analysis, Ms. Shin used Citeline's Trialtrove® and Trialpredict®, competitive intelligence resources that draw data from over 30,000 sources. The report focuses on Phase I-III industry sponsored trials located in China, Hong Kong, Japan, South Korea and/or Taiwan that were initiated or planned in 2002-2012. While Japan leads the group, as expected, with the largest number of trials, there is a clear rise in the number of trials located in China and South Korea and drop in Hong Kong.
The analysis reveals that 65% of all these trials took place in a single East Asian country, with a high of 78% of Japan's initiated studies involving only local sites compared to 55% in China. In other countries such as South Korea, the majority of trials initiated were part of a larger multinational study.
Phase 1 activity appears to be increasing while the number of Phase III trials remains steady. The most common therapeutic area is oncology, however the top indications for initiated and planned trials are not limited to cancer.
"When looking at who is conducting the trials, there is a very diverse set of players," commented Ms. Shin, "Large multinational companies such as Novartis and Roche, and local headquartered companies such as Takeda and Otsuka, initiated hundreds of their own trials, however overall there were 617 different companies with an average of only 16 trials each. And for this part of the globe, a surprisingly small number of trials involved collaborations between sponsors."
The full report also covers the indications being studied and enrollment trends by phase, location and disease as well as a detailed look into characteristics of new trials currently being planned in East Asia.
The report published today reflects Citeline's continuing efforts to bring relevant analysis to the industry through thought leadership.
To view the full analysis please download the free report – The Evolution of Clinical Research in East Asia.
Citeline delivers the pharmaceutical industry's most robust, reliable, and relevant R&D intelligence—all with direct, unlimited analyst support. Citeline's suite of fully integrated solutions features an unmatched data collection of global clinical trials, drug development pipelines, investigators and site profiles. Citeline data is drawn from over 30,000 unique sources and updated in real-time by the industry's largest team of expert analysts and editors.
Contact for Further Information
Product Marketing Manager
Share this article